Home-based sleep monitoring using a novel non-contact, radar-based biomotion sensor in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
Sarah Dietz-Terjung, Svenja Straßburg, Christoph Schöbel, Tim Schulte, Paul Dietz, Fatma Ezzahra Gahbiche, Jose Ortiz, Christian Taube, Gerhard Weinreich, Sivagurunathan Sutharsan, Matthias Welsner
{"title":"Home-based sleep monitoring using a novel non-contact, radar-based biomotion sensor in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.","authors":"Sarah Dietz-Terjung, Svenja Straßburg, Christoph Schöbel, Tim Schulte, Paul Dietz, Fatma Ezzahra Gahbiche, Jose Ortiz, Christian Taube, Gerhard Weinreich, Sivagurunathan Sutharsan, Matthias Welsner","doi":"10.1007/s11325-025-03451-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Cystic fibrosis (CF) is a life-limiting autosomal recessive disease often treated with triple CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor, ETI). Sleep disturbances are common in people with CF (pwCF). This study evaluated the Sleepiz One+, a non-contact radar-based biomotion sensor, for monitoring respiratory rate, heart rate, apnea-hypopnea index (AHI), and sleep quality in pwCF with ≥ 1 F508del allele during ETI therapy. The device's suitability for home monitoring of therapy success was also assessed.</p><p><strong>Methods: </strong>In a six-month observational study, 58 adult pwCF (2908 recordings) used the Sleepiz One + at home to collect longitudinal data on respiratory and sleep parameters during ETI therapy.</p><p><strong>Results: </strong>Significant reductions in respiratory rate and time in bed were observed after starting ETI, with respiratory rate decreases detectable within 1-5 days. Short-term respiratory rate increases corresponded with infections verified by medical records. Heart rate decreased non-significantly, and sleep efficiency improved modestly. AHI slightly decreased overall but increased in some patients, possibly linked to ETI-related weight gain.</p><p><strong>Conclusion: </strong>Sleepiz One + reliably tracked respiratory and sleep changes during ETI therapy in adult pwCF. It shows promise for early infection detection via respiratory rate monitoring, warranting further investigation.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"293"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457222/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep & breathing = Schlaf & Atmung","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11325-025-03451-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Cystic fibrosis (CF) is a life-limiting autosomal recessive disease often treated with triple CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor, ETI). Sleep disturbances are common in people with CF (pwCF). This study evaluated the Sleepiz One+, a non-contact radar-based biomotion sensor, for monitoring respiratory rate, heart rate, apnea-hypopnea index (AHI), and sleep quality in pwCF with ≥ 1 F508del allele during ETI therapy. The device's suitability for home monitoring of therapy success was also assessed.
Methods: In a six-month observational study, 58 adult pwCF (2908 recordings) used the Sleepiz One + at home to collect longitudinal data on respiratory and sleep parameters during ETI therapy.
Results: Significant reductions in respiratory rate and time in bed were observed after starting ETI, with respiratory rate decreases detectable within 1-5 days. Short-term respiratory rate increases corresponded with infections verified by medical records. Heart rate decreased non-significantly, and sleep efficiency improved modestly. AHI slightly decreased overall but increased in some patients, possibly linked to ETI-related weight gain.
Conclusion: Sleepiz One + reliably tracked respiratory and sleep changes during ETI therapy in adult pwCF. It shows promise for early infection detection via respiratory rate monitoring, warranting further investigation.
目的：囊性纤维化（CF）是一种限制生命的常染色体隐性遗传病，通常采用三联CFTR调节剂治疗（elexexaftor /tezacaftor/ivacaftor， ETI）。睡眠障碍在CF患者中很常见。本研究评估了Sleepiz One+（一种基于雷达的非接触式生物运动传感器）在ETI治疗期间监测F508del等位基因≥1的pwCF患者的呼吸频率、心率、呼吸暂停低通气指数（AHI）和睡眠质量。该设备是否适合家庭监测治疗成功也进行了评估。方法：在一项为期六个月的观察性研究中，58名成年pwCF（2908份记录）在家中使用Sleepiz One +收集ETI治疗期间呼吸和睡眠参数的纵向数据。结果：开始ETI后呼吸频率和卧床时间明显减少，呼吸频率在1-5天内可检测到下降。短期呼吸频率增加与医疗记录证实的感染相对应。心率无明显下降，睡眠效率略有提高。AHI总体上略有下降，但在一些患者中有所增加，可能与ei相关的体重增加有关。结论：Sleepiz One +可靠地跟踪成人pwCF患者在ETI治疗期间的呼吸和睡眠变化。它显示了通过呼吸频率监测早期感染检测的希望，值得进一步研究。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
